1Brilla CG,Rupp H,Funck R,et al.The renin-angiotensin-aldosterone system and myocardial collagen matrix remodeling in congestive heart failure[].European Heart Journal.1995
2Robert V,Silvestre JS,Charlemafne D,et al.Biological determinants of aldosterone-induced cardiac fibrosis in rats[].Journal of Hypertension.1995
3Dacquet C.Spirolactone inhibition of contraction and calcium channels in rat portal vein[].British Journal of Pharmacology.1987
4Bertram Pitt,Faiez Zannad,Willem J,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure[].The New England Journal of Medicine.1999
同被引文献8
1陈灏珠.实用内科学.第12版.北京:人民卫生出版社,2005,1469-1471.
2Moser M. Angiotensin-converting enzyme inhibitors, angiotensin Ⅱ receptor antagonists and calcium channel blocking agents: a review of potential benefits and adverse reactions[J]. J Am Coll Cardiol,1997,29(7):1414-1421.
3Anderson TJ. Assessment and treatment of endothelial dysfunction in humans[J]. J Am Coll Cardiol, 1999,34(3) :631-638.
4Abrams J. Role of endothelial dysfunction in coronary artery disease [J]. Am J Cardiol,1997,79(12B) :2-9.
5Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. A guide to selection[J]. Drugs,1995,49(4) :516-535.
6Goa KL,Wagstaff AJ. Losartan potassium. A review of its pharmacology ,clinical efficacy and tolerability in the management of hypertension [J]. Drugs, 1996,51 ( 5 ) :820-845.
